

Everolimus BOLERO-2

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



No QoL benefit



Serious and disabling adverse effects



Other adjustments




Only improved PFS mature data shows no OS advantage and no improved QoL



Everolimus BOLERO-2

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response


NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Treatment of HR+, HER2- advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor

Experimental Arm: Everolimus + Exemestane

Control Arm: Exemestane + placebo



